Hagens Berman Informs Investors of FDA Review Extension for Capricor Therapeutics Amid Legal Proceedings
Hagens Berman Sobol Shapiro LLP, a well-known plaintiffs' rights law firm, recently issued an important alert for investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR). This notice comes as the firm highlights the upcoming deadline of September 28, 2026, for lead plaintiffs in an ongoing securities class action. This action is set against the backdrop of significant findings regarding the company's therapies, especially their investigational cell therapy known as Deramiocel.
The FDA has amplified scrutiny over Capricor’s Biologics License Application (BLA) for Deramiocel, pushing the action date from August 22, 2026, to November 22, 2026. This delay indicates the agency's careful consideration after Capricor submitted additional data following a rather tumultuous Advisory Committee meeting that occurred in July 2026. The new submission included essential two-year open-label extension data from the Phase 3 HOPE-3 study, pointing towards an altered request that now focuses primarily on the therapy's impact on upper limb function in Duchenne muscular dystrophy (DMD) patients. This extension by the FDA can spark additional uncertainty for current and potential investors, drawing a sharp focus on the ongoing legal proceedings against the company.
According to allegations within the securities class action, Capricor executives have reportedly made materially misleading statements about the clinical data related to Deramiocel, as well as changes to their statistical analysis plan (SAP). The core of these allegations hinges on claims that Capricor altered key parameters of their study's plan without prior FDA approval before re-submitting their BLA, a move that could mislead investors regarding the likelihood of regulatory approval and expected outcomes.
The turbulence around Capricor's shares intensified following a disclosure on July 27, 2026, when the FDA released briefing documents leading up to the Advisory Committee meeting. This disclosure revealed that Capricor's previously asserted positive results had seemingly crumbled under scrutiny as the data suggested that the study did not meet specified efficacy endpoints, leading to a dramatic 64% decline in the company’s stock price in just a single day.
Hagens Berman's investigation is focused on understanding the full extent of potential investor losses linked to these alleged misleading statements and the undisclosed modifications made. The firm urges investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, and who have suffered losses as a result, to consider their legal options. Investors have until September 28, 2026, to step forward and request to be appointed as lead plaintiffs in the lawsuit. It is crucial for affected investors to note that even if they do not pursue lead status, they may still be entitled to any financial recovery achieved from the case.
In conclusion, the extension of the FDA's review period marks a critical juncture for Capricor Therapeutics. Investors who feel vulnerable due to financial losses should not hesitate to engage with legal professionals such as those from Hagens Berman. They are committed to ensuring that the implications of misleading representations by corporate management are fully explored, and remedies sought for those investors who were adversely affected by these events.
For anyone wanting to learn more or seeking legal advice, they can visit Hagens Berman's website or contact the firm directly at 844-916-0895 or via email. Furthermore, whistleblowers with knowledge of Capricor’s internal dealings are encouraged to step forward, as the SEC whistleblower program allows for the possibility of financial rewards for credible information aiding in legal actions.
Hagens Berman's commitment to upholding corporate accountability has earned them respect within the legal profession, and their recent activities surrounding Capricor Therapeutics exemplify their dedication to investors’ rights and advocacy in the face of corporate mismanagement.
The FDA has amplified scrutiny over Capricor’s Biologics License Application (BLA) for Deramiocel, pushing the action date from August 22, 2026, to November 22, 2026. This delay indicates the agency's careful consideration after Capricor submitted additional data following a rather tumultuous Advisory Committee meeting that occurred in July 2026. The new submission included essential two-year open-label extension data from the Phase 3 HOPE-3 study, pointing towards an altered request that now focuses primarily on the therapy's impact on upper limb function in Duchenne muscular dystrophy (DMD) patients. This extension by the FDA can spark additional uncertainty for current and potential investors, drawing a sharp focus on the ongoing legal proceedings against the company.
Recent Developments and Allegations
According to allegations within the securities class action, Capricor executives have reportedly made materially misleading statements about the clinical data related to Deramiocel, as well as changes to their statistical analysis plan (SAP). The core of these allegations hinges on claims that Capricor altered key parameters of their study's plan without prior FDA approval before re-submitting their BLA, a move that could mislead investors regarding the likelihood of regulatory approval and expected outcomes.
The turbulence around Capricor's shares intensified following a disclosure on July 27, 2026, when the FDA released briefing documents leading up to the Advisory Committee meeting. This disclosure revealed that Capricor's previously asserted positive results had seemingly crumbled under scrutiny as the data suggested that the study did not meet specified efficacy endpoints, leading to a dramatic 64% decline in the company’s stock price in just a single day.
Investor Reminders
Hagens Berman's investigation is focused on understanding the full extent of potential investor losses linked to these alleged misleading statements and the undisclosed modifications made. The firm urges investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, and who have suffered losses as a result, to consider their legal options. Investors have until September 28, 2026, to step forward and request to be appointed as lead plaintiffs in the lawsuit. It is crucial for affected investors to note that even if they do not pursue lead status, they may still be entitled to any financial recovery achieved from the case.
In conclusion, the extension of the FDA's review period marks a critical juncture for Capricor Therapeutics. Investors who feel vulnerable due to financial losses should not hesitate to engage with legal professionals such as those from Hagens Berman. They are committed to ensuring that the implications of misleading representations by corporate management are fully explored, and remedies sought for those investors who were adversely affected by these events.
For anyone wanting to learn more or seeking legal advice, they can visit Hagens Berman's website or contact the firm directly at 844-916-0895 or via email. Furthermore, whistleblowers with knowledge of Capricor’s internal dealings are encouraged to step forward, as the SEC whistleblower program allows for the possibility of financial rewards for credible information aiding in legal actions.
Hagens Berman's commitment to upholding corporate accountability has earned them respect within the legal profession, and their recent activities surrounding Capricor Therapeutics exemplify their dedication to investors’ rights and advocacy in the face of corporate mismanagement.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.